PPD bolsters suite with Acurian acquisition
By Mia Burns (firstname.lastname@example.org)
Contract research organization PPD has acquired Acurian with the hopes of providing clients with industry-leading services that accelerate patient enrollment and support company strategies for data-driven feasibility, site selection, and enrollment delivery. Executives are not disclosing financial terms.
“Acurian is a well-managed, disciplined organization, and its best-in-class approach to patient recruitment will be an excellent complement to PPD’s clinical development expertise,” says William Sharbaugh COO, PPD. “Acurian’s expertise spans multiple therapeutic areas, aligning with PPD’s broad therapeutic area expertise. Our combined experience and capabilities will add value for PPD clients across a wide range of research programs.”
According to company executives, Acurian will continue to operate under its own name as a separate business unit with its existing management team led by Rick Malcolm, who has served as Acurian’s chief executive officer since 2005. This course of action will allow for the “leveraging both companies’ strong name recognition and reputation within the industry for deep expertise and quality service,” Sharbaugh told R&D Pharma Business Connect.
Acurian provides services around the world. “Acurian can deploy recruitment and retention services worldwide, including in emerging markets such as Brazil,” Sharbaugh says. “The exact type of service delivery is contingent on country and ethics committee guidance and regulations. Acurian’s expertise aligns with PPD’s global footprint, which includes operations in 50 countries.”
“We are excited about the opportunity to become part of a leading global contract research organization,” Malcolm said. “Combining Acurian’s 15 years of experience in successfully innovating to meet the challenges of patient enrollment and retention with PPD’s full spectrum of drug development services will enable us to merge the expertise of both organizations and offer clients unique solutions for clinical trial feasibility studies and patient recruitment and retention.”
Posted: September 2013